Abstract According to the new World Health Organization (WHO) classification (2008), chronic myeloid malignancies are divided in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and overlap MDS/MPN cases. From morphological aspects, these categories show overlaps. To evaluate whether these morphological similarities have genetic parallels, we investigated 1,851 cases with suspected/confirmed myelodysplastic or myeloproliferative diseases by chromosome banding and molecular analyses. Cytogenetics revealed aberrant karyotypes in 354 patients (19.1% of the original cohort) who were the basis of further analysis. The distribution of chromosomal aberrations differed significantly between categories. Isolated +9 and gain of 9p were exclusively observed in MPN (+9: 10/93; 11%; p<0.001; +9p: 6/93; 7% of all aberrant MPN cases) but were not detected in MDS or MDS/MPN (p=0.001). Isolated del(5q) (p=0.002), −7 in combination with other aberrations (p=0.016), and complex aberrations (p=0.003) were 2.9-to 7.5-fold more frequent in MDS than in MPN. Trisomies 8 and 21 and del(20q) were comparably frequent in both subgroups. Interestingly, the MDS/MPN overlap cohort showed a higher frequency of −7 accompanied by other aberrations (3/17; 18% of all aberrant cases; p=0.001), i(17)(q10) (2/17; 12%; p=0.013), and +21 (2/17; 12%; p=0.013) when compared to MPN or MDS only. These differences support the category for MDS/MPN within the new WHO classification. Overlaps between the diverse disorders were seen also for the JAK2V617F (MPN 66/89; 74%; MDS/MPN 4/14; 29%; MDS 2/63; 3%) and NRAS mutations (MDS 2/67; 3%; MPN 2/4; MDS/MPN 1/1). In conclusion, cytogenetics and molecular genetics show overlaps in varying proportions of MDS and MPN cases which might indicate common pathways in their etiology. Some markers are strongly associated with one of these disorders and can be helpful for differential diagnosis especially in difficult cases.
Introduction
According to the new World Health Organization (WHO) classification (2008), chronic myeloid malignancies are divided into three main categories: myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and a further category which shows overlapping characteristics of both MDS and MPN and which is classified as myelodysplastic/myeloproliferative neoplasms (MDS/ MPN; WHO classification, 2008, Chapter 4) [1] . This third category has been introduced by WHO due to the frequent cytological, histomorphological, clinical, and laboratory overlaps of myelodysplastic and myeloproliferative disorders [1, 2] and includes chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia, the subcategory "myelodysplastic/myeloproliferative neoplasms, unclassifiable" (MDS/MPN, U), and the rare refractory anemia with ring sideroblasts and thrombocytosis [1, 3, 4] .
In contrast to chronic myeloid leukemia, which is clearly defined by the BCR-ABL rearrangement, karyotype abnormalities are found in ∼55% of MDS cases [5, 6] and in 5-45% of the Philadelphia negative MPN only [7, 8] , with the highest frequency in primary myelofibrosis (PMF; ∼35%) and the lowest in essential thrombocythemia (ET; <5%). In the "myelodysplastic/myeloproliferative neoplasm, unclassifiable" category (MDS/MPN, U) where the frequency of chromosomal aberrations is especially difficult to determine, ∼30% frequencies were reported [8] . Most chromosomal aberrations are not specific for single entities [6] [7] [8] but can occur in MDS as well as in MPN, e.g., gain of chromosome 8, loss of chromosome 7, or 20q deletions [6, 7, 9] . Such overlaps are also seen on the molecular level: the JAK2V617F mutation, which is observed mainly in the MPN with frequencies of >95% in polycythemia vera (PV) and >50% in ET and PMF [10] [11] [12] [13] [14] , was also detected in 8-15% of MDS cases, respectively [15] . Internal tandem duplications of the FLT3 gene (FLT3-ITD) were described in ≥10% of all advanced MDS [16] and in one study in ∼10% of BCR-ABL-negative MPN patients [17] .
Thus, overlaps of myelodysplastic and myeloproliferative neoplasms seem not to be limited to morphology but exist as well on the cytogenetic and molecular genetic level. This suggests overlaps in the leukemogenic pathways in part of all MPN and MDS cases. To further analyze the pattern of genetic alterations in these categories, we here investigated a total of 1,851 cases with confirmed or suspected myelodysplastic or myeloproliferative diseases by chromosome banding and molecular analyses. The aim of the study was to describe which overlaps exist as well from cytogenetic and molecular genetic aspects and whether specific findings allow a distinct assignment of difficult MDS and MPN cases.
Patients
In total, 1,851 patients (889 males, 962 females) with confirmed or suspected myeloproliferative or myelodysplastic disorders were included in the study. Range of age was 4.8 -93.9 years (median 67.3 years). Patients' samples were referred for diagnostic investigations to the Munich Leukemia Laboratory (MLL) between August 2005 and September 2007. This includes informed consent forms for cytogenetic and molecular genetic workup. Patients also agreed that data could be used for further workup and research projects.
Part of the patients had been included in two previous studies [18, 19] .
In total, 512 patients were classified as MDS, 618 patients as MPN, and 61 patients had an MDS/MPN overlap based on clinical data, cytomorphology, histology (if available), and cytogenetic or molecular genetic aberrations detectable. Furthermore, a diagnosis of MDS was only suspected in 293 patients (MDS-s) and of MPN in 367 patients (MPN-s), as not all requested cytomorphological criteria were fulfilled. The classification followed WHO 2001 and 2008, respectively [1, 20] .
In more detail, the MDS cohort was composed by the following morphological subtypes: refractory anemia (RA): n=17; RA with ring sideroblasts: n=20; refractory cytopenia with multilineage dysplasia (RCMD): n=65; RCMD-RS: n=48; refractory anemia with excess of blasts: n=259; MDS with an isolated del(5q): n=20. Eighty-three MDS cases could not be clearly classified (MDS, U). The MPN cohort was composed by the following subentities: PV: n=80, ET: n=133, PMF: n=18, and MPN, U (unclassifiable MPN): n=387.
Methods
Chromosome banding analyses in combination with fluorescence in situ hybridization techniques were performed in all 1,851 patients according to standard procedures.
[21] Patients were categorized in the following chromosomal subgroups: −Y, structural gain of 1q, deletions of 5q and 20q, −7, +8, +9, which were considered separately depending on the occurrence as isolated anomaly ("sole") or in combination with other abnormalities ("combined"). Other categories were gain of 9p (due to unbalanced rearrangements, not to gain of whole chromosome 9), del(11q), del(12p), del(13q), i (17q), balanced translocations, and complex aberrations (≥3 clonal chromosomal abnormalities; Table 1 ). Patients with abnormalities of chromosomes 5 or 7 and evidence of at least two additional clonal abnormalities were included in the cohort with complex aberrations.
Screening for the JAK2V617F mutation was performed by a melting-point-based polymerase chain reaction assay [22] . Molecular analyses for the FLT3-ITD [23] , partial tandem duplications of the MLL gene (MLL-PTD) [24] , NRAS [25] , and NPM1 (nucleophosmin) mutations [26] were performed as previously described in variable proportions of patients (Table 2) .
For comparison of dichotomous variables between different groups (MDS, MPN, and MDS/MPN), the twosided Fisher's exact test was used. Statistical analysis was performed with the SPSS software (version 14.0; SPSS, Chicago, IL, USA).
Results

Distribution of chromosomal aberrations
Karyotype aberrations were detected in 354 patients (19.1% of all patients) who were the basis of further investigation.
The highest aberration rate was observed in 181/512 in MDS (35.4%), being followed by 17/61 (27.9%) in MDS/ MPN (p<0.001). In the MPN, chromosomal aberrations were detected in 93/618 (15.0%; p<0.01). Finally, the chromosomal aberration rates were 27/367 in MPN-s (7.4%) and 36/293 (12.3%) in the MDS-s cases.
When all cohorts were considered, most frequent were −Y (n=57), +8 as sole (n=42) or combined aberration (n=31), and del(5q) as sole (n=35) or combined aberration (n=30). Complex aberrations were observed in 55 cases ( Table 1) .
Comparison of chromosomal aberrations in MDS and MPN
The distribution of chromosomal aberrations in the cytogenetic aberrant cases was compared between the diverse entities ( 
Patients with suspected myelodysplastic or myeloproliferative diseases
The chromosomal aberration rate was 36/293 in the MDS-s (12.3%) and 27/367 in the MPN-s (7.4%) cases. In the 
Molecular analyses
MDS
In the MDS cohort, there was a low frequency of NRAS mutations in cases analyzed (2/67; 3%) and MLL-PTD (5/86; 6%). There was no FLT3-ITD in 91 MDS cases analyzed. In the cohort with suspected MDS (MDS-s), one patient (1/19; 5%) was MLL-PTD mutated. NPM1 mutation screening was negative in all cohorts.
MPN
In the MPN cohort, there was a high frequency of the JAK2V617F (66/89; 74%), which was significantly more frequent when compared to MDS/MPN (4/14; 29%; p=0.01) or MDS (2/63; 3%; p<0.01). In the cohort with suspected MPN (MPN-s), 15/26 patients (58%) were JAK2V617F-mutated. When all cohorts were considered, the JAK2V617F mutation was significantly correlated with the occurrence of a sole +9 (p<0.001).
MDS/MPN
MDS/MPN cases were characterized by a 4/14 (29%) frequency of JAK2V617F. Also, there was one NRASmutated case (one patient being investigated only), and one of seven patients had an MLL-PTD (14%).
Discussion
In this study, we evaluated whether the clinical and morphological overlaps which are seen between the categories of myelodysplastic and myeloproliferative diseases [1, 3, 4] show parallel or discriminating results on the cytogenetic and molecular level. Thus, in 1,851 patients with diverse myelodysplastic or myeloproliferative disorders, the results of cytogenetic and molecular analyses were correlated with the respective diagnostic categories according to the WHO classification. The aberrant karyotype case rates in the diverse categories (MDS 35.4%; MPN 15.0%) were lower than in previous studies in MDS or MPN [6, 7, 27, 28] . This probably should be seen in correlation to the time points of investigation during the course of disease, as in the mentioned studies patients were included in all stages of disease, whereas referral in the present study was mainly from outpatient practices early in the course of the disease and only in a small proportion from hospitals that normally treat patients with MDS or MPN in later stages. First, significant differences in the distribution of the chromosomal aberrations were observed between myelodysplastic and myeloproliferative disorders, when only the 354 patients with aberrant karyotypes were evaluated: isolated trisomy 9 and structural gain of 9p were exclusively observed in MPN (+9 10.8%; p<0.001; +9p 6.5%; p=0.001), whereas they were not detected in MDS or MDS/MPN. This was in accordance to previous studies where trisomy 9 was identified as one of the most frequent cytogenetic abnormality in the MPN [7, 19] .
In contrast, isolated 5q deletions, −7 in combination with other anomalies, and complex aberrations were 2.9-to 7.5-fold more frequent in MDS when compared to MPN. Interestingly, loss of chromosome Y was 3.1-fold more frequently observed in MDS and had a low frequency in the MPN. This chromosomal loss can be seen as well physiologically in elderly males. Nevertheless, median age was comparable in both the MDS and MPN cohorts (69.3 and 67.2 years, respectively), which allows the hypothesis that increased frequency of a sole loss of chromosome Y in MDS when compared to MPN may be of relevance. As it is also used as a prognostic parameter in the IPSS, we can confirm its increased frequency in MDS with our data [29] . Thus, the respective aberrations show preference for MDS although overlaps with single MPN cases exist. The finding of isolated 5q deletions in MDS and MPN in parallel with significant preponderance in MDS cases is in accordance to previous observations that some 5q cases with increased myelofibrosis are JAK2V617F-mutated and suggests an overlap of myelodysplastic and myeloproliferative features in this specific subset [30, 31] .
Balanced translocations had a rather low frequency in the MDS cases (5.5%) also when compared to the MPN (16.1%), which was in correlation to previous observations that in MDS most chromosomal alterations are unbalanced and result from structural or numerical losses or gains [6] .
Gain of chromosome 8 and 20q deletions as isolated or combined anomalies, del(11q), i(17)(q10), and trisomy 21 showed comparable frequencies in both MDS and the MPN. Especially trisomy 8-which was identified here in 8.6-11.0% of all MPN and MDS cases-had previously been reported to be unspecifically associated to various myeloid malignancies and to confer an intermediate prognosis when being found as sole abnormality or in noncomplex karyotypes in acute myelogenous leukemia (AML) [6, 27, 32] . In the analysis of Farag et al., trisomy 8 was shown to represent a poor prognostic parameter when patients did not receive allogeneic stem cell transplantation and as an intermediate risk feature in case of allogeneic stem cell transplantation [33] .
Losses of tumor suppressor genes were hypothesized as leukemogenic mechanism in cases with the del(20q) due to the identification of some candidate genes in the involved region [34] . In MDS, isolated 20q deletions were found to be prognostically favorable [27] [28] [29] , whereas in the MPN an impact on prognosis so far was not determined [35] .
These cytogenetic parallels emphasize common pathways in the origin of the myelodysplastic and the myeloproliferative disorders in at least a subset of cases. Also, they support the hypothesis that the identified cytogenetic mechanisms are only part of the complex network of aberrations being involved in leukemogenesis in MDS or MPN. So far, unidentified cooperating genetic mutations or epigenetic mechanisms might be responsible for the different morphological and clinical phenotypes in these cases showing a mutational overlap.
Second, the cohort MDS/MPN as the overlap category of myelodysplastic and myeloproliferative features showed a diverse distribution of the chromosomal abnormalities in comparison to both the MDS and MPN cohorts. Loss of chromosome 7 in combination with other anomalies, isochromosome 17q, and trisomy 21 were more frequent in MDS/MPN than in MPN or in MDS. In contrast, isolated 5q deletions showed a lower frequency in MDS/MPN than in MDS.
Another result of this study was the observation that overlaps between the diverse myeloid disorders exist as well from the molecular perspective. Although the JAK2V617F mutation showed a 25-fold higher incidence in the MPN than in MDS, there was a low incidence of mutated cases in MDS in this study (3%) as in previous analyses (Steensma et al. 5%, Jelinek et al. 1%) [12, 15] which is indicative for common molecular mechanisms in the MPN and a small MDS subset.
Considering other molecular markers in MDS, the 3% frequency of NRAS mutations in MDS was lower when compared to previous studies where frequencies were varying between 7% and 48% probably due to different inclusion criteria [36] [37] [38] and confirmed our own previous results [18] . With respect to the FLT3-ITD, no case was detected in MDS in this study. This has to be seen in consideration of the limited number of analyzed patients (n=91), as low frequencies of 2.5-8% FLT3-ITD-mutated patients had been previously reported in MDS [16, 39] . Nevertheless, there was one accelerated MPN patient carrying an FLT3-ITD (4%), which gives confirmation to previous studies where the FLT3-ITD were detected in ∼10% in BCR-ABL negative MPN patients in chronic or blast phase [17] . MLL-PTD were found in 6% of the MDS patients. The parallel finding of these mutations in MDS and in AML [18, 23, 40, 41] emphasizes the vicinity of both disorders in part of the cases.
In conclusion, similar to cytomorphology, cytogenetics and molecular genetics show overlaps in varying proportions of MDS and MPN cases which indicate common pathways in the etiology of both disorders. Further, some markers show a strong association with one of these disorders which can be helpful in the differential diagnosis in some cases.
